Federal Register / Vol. 87, No. 116 / Thursday, June 16, 2022 / Notices 36339 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Beta Globin Mimetic Peptides and 

Their Use 

Description of Technology 

Feedback vasodilation by 

endothelium-derived nitric oxide (NO) 

is under the regulation of globins. 

Inventors discovered that not only the 

alpha globin but also the beta globin 

subunits of hemoglobin are expressed in 

the human artery wall, with beta globin 

interacting directly with endothelial 

nitric oxide synthase (eNOS). This 

discovery of tetrameric hemoglobin 

binding to eNOS has led inventors to 

develop novel mimetic peptides that 

disrupt the binding of beta globin to 

eNOS, diminishing the ability of 

hemoglobin to restrict NO release and 

thereby enhancing NO-mediated 

feedback vasodilation. These agents can 

be used to increase NO signaling from 

endothelial cells and thus inhibit, 

prevent, or reverse vasoconstriction. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Novel peptides to treat vascular 

diseases characterized by 

vasoconstriction, excess alpha 

adrenergic signaling, or insufficient 

nitric oxide signaling. Applications 

could range from cerebral vasospasm to 

pulmonary hypertension to chronic 

kidney disease to transfusion medicine 

to erectile dysfunction to exercise 

physiology. 

Competitive Advantages 

• New pathway for regulation of 

vasoconstriction/vasodilation. 

• Enhancement of NO release at the 

junction between the endothelial cell 

and smooth muscle cell may provide 

greater potency and fewer off-target 

effects than other forms of NO delivery. 

Development Stage: Peptides have 

been tested in human and canine 

arteries ex vivo. 

Inventors: Drs. Hans Ackerman, 

Steven Brooks, Phillip Cruz, all of 

NIAID. 

Publications: ‘‘Hemoglobin Interacts 

with Endothelial Nitric Oxide Synthase 

to Regulate Vasodilation in Human 

Resistance Arteries’’, https://doi.org/ 

10.1101/2021.04.06.21255004. 

Intellectual Property: HHS Reference 

No. E–060–2022–0–US–01—U.S. 

Provisional Application No. 63/328,615, 

filed April 7, 2022. 

Licensing Contact: To license this 

technology, please contact Peter Tung at 

240–669–5483, or peter.tung@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize the invention. For 

collaboration opportunities, please 

contact Peter Tung at 240–669–5483; 

peter.tung@nih.gov. 

Dated: June 9, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–12922 Filed 6–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; Review of NRSA Institutional 

Postdoctoral Training Grant (T32) 

Applications. 

Date: July 15, 2022. 

Time: 9:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of General 

Medical Sciences, Natcher Building, 45 

Center Drive, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: John J. Laffan, Scientific 

Review Officer, Office of Scientific Review, 

National Institute of General Medical 

Sciences, National Institutes of Health, 

Natcher Building, 45 Center Drive, Room 

3AN18J, Bethesda, MD 20892, 301–594– 

2773, laffanjo@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives; 93.859, 

Biomedical Research and Research Training, 

National Institutes of Health, HHS) 

Dated: June 10, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12923 Filed 6–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases Special Emphasis Panel: NIAMS 

RE–JOIN UCT2 Review Meeting. 

Date: July 12, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Arthritis, 

Musculoskeletal and Skin Diseases, 6701 

Democracy Boulevard, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Kan Ma, Ph.D., Scientific 

Review Officer, Scientific Review Branch, 

National Institute of Arthritis, 

Musculoskeletal and Skin Diseases, NIH, 

6701 Democracy Boulevard, Suite 814, 

Bethesda, MD 20892, 301–451–4838, mak2@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 


khammond on DSKJM1Z7X2PROD with NOTICES